Ivermectin: is necessary to think outside the box to reposition it
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/10611 |
Resumo: | Ivermectin (IVM) is a drug derived from avermectin B1 with high permeability and low solubility. It is used as a broad spectrum antiparasitic and studies reveal promising antiviral and anti-inflammatory activities. In addition, formulations and delivery systems have been applied to optimize the solubility and bioavailability of the drug. Thus, it is intended to highlight the development of new formulations and delivery systems containing IVM in view of not only the technological benefits, but also the benefits of effectiveness in the face of distinct disorders for which the drug was not originally applied. The delivery systems have been applied to optimize the solubility and bioavailability of IVM, reduce its cytotoxicity and increase the therapeutic effect in smaller doses. In this sense, the literature reveals different formulations and delivery systems containing IVM that aim to improve their physical-chemical properties, such as microparticles, microspheres, liposomes, microemulsions, in situ formation gel, controlled and prolonged release formulations, solid dispersion and micelles mixed. As a potential antiviral agent, this drug inhibits the replication of viral strains and reduces serum levels of viral protein in in vitro and in vivo studies; when incorporated into liposomes, efficacy was high and toxicity reduced. IVM has shown potential for application in dermatological disorders due to anti-inflammatory activity, highlighting the successful repositioning for the treatment of papulopustular rosacea. Therefore, repositioning older drugs to treat common or rare diseases, as well as in the face of an urgent need, becomes an attractive tool in the scope of drug research and development. |
id |
UNIFEI_74e7bda75b84e22d405dcb5dbd29d9e7 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/10611 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Ivermectin: is necessary to think outside the box to reposition itIvermectina: es necesario pensar fuera de la caja para reposicionarlaIvermectina: é preciso pensar fora da caixa para reposicioná-laIvermectinaAntiparasitárioAntiviralAnti-inflamatórioReposicionamento de Medicamentos.IvermectinAntiparasiticAntiviralAnti-inflammatoryRepositioning of Medicines.IvermectinaAntiparasitarioAntivíricoAntiinflamatorioReposicionamiento de medicamentos.Ivermectin (IVM) is a drug derived from avermectin B1 with high permeability and low solubility. It is used as a broad spectrum antiparasitic and studies reveal promising antiviral and anti-inflammatory activities. In addition, formulations and delivery systems have been applied to optimize the solubility and bioavailability of the drug. Thus, it is intended to highlight the development of new formulations and delivery systems containing IVM in view of not only the technological benefits, but also the benefits of effectiveness in the face of distinct disorders for which the drug was not originally applied. The delivery systems have been applied to optimize the solubility and bioavailability of IVM, reduce its cytotoxicity and increase the therapeutic effect in smaller doses. In this sense, the literature reveals different formulations and delivery systems containing IVM that aim to improve their physical-chemical properties, such as microparticles, microspheres, liposomes, microemulsions, in situ formation gel, controlled and prolonged release formulations, solid dispersion and micelles mixed. As a potential antiviral agent, this drug inhibits the replication of viral strains and reduces serum levels of viral protein in in vitro and in vivo studies; when incorporated into liposomes, efficacy was high and toxicity reduced. IVM has shown potential for application in dermatological disorders due to anti-inflammatory activity, highlighting the successful repositioning for the treatment of papulopustular rosacea. Therefore, repositioning older drugs to treat common or rare diseases, as well as in the face of an urgent need, becomes an attractive tool in the scope of drug research and development.La ivermectina (IVM) es un fármaco derivado de la avermectina B1 con alta permeabilidad y baja solubilidad. Se utiliza como un antiparasitario de amplio espectro y los estudios revelan actividades antivirales y antiinflamatorias prometedoras. Además, se han aplicado formulaciones y sistemas de administración para optimizar la solubilidad y biodisponibilidad del fármaco. Por lo tanto, se pretende resaltar el desarrollo de nuevas formulaciones y sistemas de administración que contienen MIV en vista no solo de los beneficios tecnológicos, sino también de los beneficios de la efectividad frente a distintos trastornos para los que el fármaco no se aplicó originalmente. Los sistemas de administración se han aplicado para optimizar la solubilidad y biodisponibilidad de IVM, reducir su citotoxicidad y aumentar el efecto terapéutico en dosis más pequeñas. En este sentido, la literatura revela diferentes formulaciones y sistemas de liberación que contienen MIV que tienen como objetivo mejorar sus propiedades físico-químicas, tales como micropartículas, microesferas, liposomas, microemulsiones, gel de formación in situ, formulaciones de liberación controlada y prolongada, dispersión sólida y micelas. mezclado. Como potencial agente antiviral, este fármaco inhibe la replicación de cepas virales y reduce los niveles séricos de proteína viral en estudios in vitro e in vivo; cuando se incorporó en liposomas, la eficacia fue alta y la toxicidad reducida. IVM ha mostrado potencial de aplicación en trastornos dermatológicos debido a su actividad antiinflamatoria, destacando el exitoso reposicionamiento para el tratamiento de la rosácea papulopustulosa. Por tanto, el reposicionamiento de fármacos más antiguos para tratar enfermedades comunes o raras, así como ante una necesidad urgente, se convierte en una herramienta atractiva en el ámbito de la investigación y el desarrollo de fármacos.A ivermectina (IVM) é um fármaco derivado da avermectina B1 de alta permeabilidade e baixa solubilidade. É utilizado como antiparasitário de amplo espectro e estudos revelam promissoras atividades antiviral e anti-inflamatória. Além disso, formulações e sistemas de liberação têm sido aplicados para otimizar a solubilidade e biodisponibilidade do fármaco. Desse modo, pretende-se destacar o desenvolvimento de novas formulações e sistemas de liberação contendo a IVM tendo em vista não só os benefícios tecnológicos, mas também os proveitos de efetividade diante de distúrbios distintos para os quais o fármaco não foi originalmente aplicado. Os sistemas de liberação têm sido aplicados para otimizar a solubilidade e biodisponibilidade da IVM, reduzir sua citotoxicidade e aumentar o efeito terapêutico em doses menores. Nesse sentido, a literatura revela distintas formulações e sistemas de liberação contendo IVM que visam melhorar suas propriedades físico-químicas, tais como micropartículas, microesferas, lipossomas, microemulsões, gel de formação in situ, formulações de liberação controlada e prolongada, dispersão sólida e micelas mistas. Como potencial agente antiviral, este fármaco inibe a replicação de cepas virais e reduz níveis séricos de proteína viral em estudos in vitro e in vivo; quando incorporada em lipossomas, a eficácia foi elevada e toxicidade reduzida. A IVM demonstrou potencial para aplicação em distúrbios dermatológicos devido a atividade anti-inflamatória, destacando o reposicionamento bem sucedido para o tratamento de rosácea papulopustular. Portanto, reposicionar fármacos mais antigos para tratar doenças comuns ou raras, bem como diante de uma urgente necessidade, torna-se uma ferramenta atraente no âmbito da pesquisa e desenvolvimento de medicamentos.Research, Society and Development2020-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1061110.33448/rsd-v9i11.10611Research, Society and Development; Vol. 9 No. 11; e68191110611Research, Society and Development; Vol. 9 Núm. 11; e68191110611Research, Society and Development; v. 9 n. 11; e681911106112525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/10611/9232Copyright (c) 2020 Thais Cruz Ramalho; Rayran Walter Ramos de Sousa; Duanne Mendes Gomes; André Luís Menezes Carvalho; Railson Pereira Souza; Hercília Maria Lins Rolimhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRamalho, Thais CruzSousa, Rayran Walter Ramos deGomes, Duanne MendesCarvalho, André Luís MenezesSouza, Railson PereiraRolim, Hercília Maria Lins2020-12-10T23:37:57Zoai:ojs.pkp.sfu.ca:article/10611Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:32:38.715174Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Ivermectin: is necessary to think outside the box to reposition it Ivermectina: es necesario pensar fuera de la caja para reposicionarla Ivermectina: é preciso pensar fora da caixa para reposicioná-la |
title |
Ivermectin: is necessary to think outside the box to reposition it |
spellingShingle |
Ivermectin: is necessary to think outside the box to reposition it Ramalho, Thais Cruz Ivermectina Antiparasitário Antiviral Anti-inflamatório Reposicionamento de Medicamentos. Ivermectin Antiparasitic Antiviral Anti-inflammatory Repositioning of Medicines. Ivermectina Antiparasitario Antivírico Antiinflamatorio Reposicionamiento de medicamentos. |
title_short |
Ivermectin: is necessary to think outside the box to reposition it |
title_full |
Ivermectin: is necessary to think outside the box to reposition it |
title_fullStr |
Ivermectin: is necessary to think outside the box to reposition it |
title_full_unstemmed |
Ivermectin: is necessary to think outside the box to reposition it |
title_sort |
Ivermectin: is necessary to think outside the box to reposition it |
author |
Ramalho, Thais Cruz |
author_facet |
Ramalho, Thais Cruz Sousa, Rayran Walter Ramos de Gomes, Duanne Mendes Carvalho, André Luís Menezes Souza, Railson Pereira Rolim, Hercília Maria Lins |
author_role |
author |
author2 |
Sousa, Rayran Walter Ramos de Gomes, Duanne Mendes Carvalho, André Luís Menezes Souza, Railson Pereira Rolim, Hercília Maria Lins |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Ramalho, Thais Cruz Sousa, Rayran Walter Ramos de Gomes, Duanne Mendes Carvalho, André Luís Menezes Souza, Railson Pereira Rolim, Hercília Maria Lins |
dc.subject.por.fl_str_mv |
Ivermectina Antiparasitário Antiviral Anti-inflamatório Reposicionamento de Medicamentos. Ivermectin Antiparasitic Antiviral Anti-inflammatory Repositioning of Medicines. Ivermectina Antiparasitario Antivírico Antiinflamatorio Reposicionamiento de medicamentos. |
topic |
Ivermectina Antiparasitário Antiviral Anti-inflamatório Reposicionamento de Medicamentos. Ivermectin Antiparasitic Antiviral Anti-inflammatory Repositioning of Medicines. Ivermectina Antiparasitario Antivírico Antiinflamatorio Reposicionamiento de medicamentos. |
description |
Ivermectin (IVM) is a drug derived from avermectin B1 with high permeability and low solubility. It is used as a broad spectrum antiparasitic and studies reveal promising antiviral and anti-inflammatory activities. In addition, formulations and delivery systems have been applied to optimize the solubility and bioavailability of the drug. Thus, it is intended to highlight the development of new formulations and delivery systems containing IVM in view of not only the technological benefits, but also the benefits of effectiveness in the face of distinct disorders for which the drug was not originally applied. The delivery systems have been applied to optimize the solubility and bioavailability of IVM, reduce its cytotoxicity and increase the therapeutic effect in smaller doses. In this sense, the literature reveals different formulations and delivery systems containing IVM that aim to improve their physical-chemical properties, such as microparticles, microspheres, liposomes, microemulsions, in situ formation gel, controlled and prolonged release formulations, solid dispersion and micelles mixed. As a potential antiviral agent, this drug inhibits the replication of viral strains and reduces serum levels of viral protein in in vitro and in vivo studies; when incorporated into liposomes, efficacy was high and toxicity reduced. IVM has shown potential for application in dermatological disorders due to anti-inflammatory activity, highlighting the successful repositioning for the treatment of papulopustular rosacea. Therefore, repositioning older drugs to treat common or rare diseases, as well as in the face of an urgent need, becomes an attractive tool in the scope of drug research and development. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-11-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/10611 10.33448/rsd-v9i11.10611 |
url |
https://rsdjournal.org/index.php/rsd/article/view/10611 |
identifier_str_mv |
10.33448/rsd-v9i11.10611 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/10611/9232 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 9 No. 11; e68191110611 Research, Society and Development; Vol. 9 Núm. 11; e68191110611 Research, Society and Development; v. 9 n. 11; e68191110611 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052743382204416 |